Biocon inks out-licensing agreement with Ajanta to market Semaglutide in 26 countries

Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia

Ipsen’s FALKON trial falls short in rare FOP study, offers key insights

FOP is a rare genetic disorder caused by mutations in the ALK2 kinase

GSK strikes deal with US to lower prescription drug costs & boost respiratory medicine access

GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%

Emcure Pharma launches weight loss drug Poviztra in India

Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management

Samsung Biologics strengthens U.S. presence with acquisition of GSK’s Human Genome Sciences or $280 million

Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs

Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch

Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026

Replacing confusion with clarity: Global Cancer Care launches Mumbai ops to tackle detection delays

The initiative is focused on a problem that continues to plague cancer outcomes in India

Merck strikes historic deal with Trump admin to lower drug costs for Americans

Pfizer and Cipla forge exclusive marketing and distribution pact for key brands in India

This marks the first partnership between Pfizer and Cipla in India

Fortis invests Rs. 840 crore for 300+ beds in Bengaluru

Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore